Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
Status:
Not yet recruiting
Trial end date:
2024-01-09
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy
confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults
with NASH.